


# Liquiritin Protects Against Cardiac Fibrosis After Myocardial Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF- $\kappa$ B Signaling Pathway [Letter]

Hasta Handayani Idrus <sup>\*</sup>, Sunarno<sup>\*</sup>

Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Cibinong Science Center, Bogor, West Java, Indonesia

<sup>\*</sup>These authors contributed equally to this work

Correspondence: Hasta Handayani Idrus, Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Genomic Building, Cibinong Science Center, Jl. Raya Bogor No. 490, Cibinong – Bogor Km. 46, Bogor, West Java, Indonesia, Email [hastahandayani99@gmail.com](mailto:hastahandayani99@gmail.com)

## Dear editor

We read with interest the study by Xue Han et al about Liquiritin Protects Against Cardiac Fibrosis After Myocardial Infarction by Inhibiting CCL5 Expression and the NF- $\kappa$ B Signaling Pathway.<sup>1</sup> We congratulate the authors who have made a major contribution to the world of health, especially heart disease. Based on the results obtained in this study the researchers concluded that Liquiritin (LQ) can improve cardiac function, reduce the size of myocardial infarction, attenuate cardiac pathological damage, suppress oxidative stress and inflammatory response, and decrease the expression of biomarkers related to MF. The method used by Xue Han et al in this study is appropriate so that researchers can draw conclusions that Liquiritin (LQ) compounds can significantly reduce oxidative stress and inflammatory responses. We would like to provide input to researchers who wish to carry out the same research regarding LQ compounds to be able to first conduct a toxicity test on each compound from the extract to be tested because this can minimize the side effects of the compound if the test is used excessively.<sup>2</sup>

Xue Han et al in this study gave mice the LQ compound orally once a day for 14 days and then performed biochemical tests, histopathological observations, ELISA, and Western blotting analysis. The method used is appropriate and appropriate. We would like to provide information that is also related to this method, namely endothelial-mesenchymal transition (EndMT) examination, which can measure Transforming growth factor  $\beta$  (TGF- $\beta$ ) to determine the severity of heart damage due to myocardial infarction by inducing EndMT in human umbilical vein endothelial cells, who were pretreated with RLX, 200 ng·mL<sup>-1</sup>, then with Notch inhibitor. Transwell cell migration was used to evaluate cell migration. CD31 and vimentin content was determined by fluorescence immuno-staining and subsequent Western blot analysis. Notch protein levels were checked by Western blot analysis.<sup>3,4</sup>

In conclusion, the results obtained by Xue Han et al, namely that LQ compounds can improve cardiac and EKG performance, reduce heart weight index, and reduce levels of heart-specific markers such as CK, CK-MB, LDH, cTnI, and BNP are appropriate. We would like to provide input for researchers who wish to carry out the same or related research to be able to continue this research on other degenerative diseases because this compound has many benefits that can continue to be developed in the future.

## Disclosure

The authors report no conflicts of interest in this communication.

## References

1. Han X, Yang Y, Zhang M, et al. Liquiritin protects against cardiac fibrosis after myocardial infarction by inhibiting CCL5 expression and the NF- $\kappa$ B signaling pathway. *Drug Des Devel Ther.* 2022;6:4111–4125. doi:10.2147/DDDT.S386805
2. Chen X, Xia X, Dong T, Lin Z, Du L, Zhou H. Trimetazidine reduces cardiac fibrosis in rats by inhibiting NOX2-mediated endothelial-to-mesenchymal transition. *Drug Des Devel Ther.* 2022;16:2517–2527. doi:10.2147/DDDT.S360283
3. Zhou X, Chen X, Cai JJ, et al. Relaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway. *Drug Des Devel Ther.* 2015;9:4599–4611. doi:10.2147/DDDT.S85399
4. Idrus HH, Hatta M, Febriza A, Novarina V. Antibacterial activities of sapodilla fruit extract inhibiting salmonella typhi on mice Balb/c. *Int J Appl Pharm.* 2019;11(5). doi:10.22159/ijap.2019.v11s5.T0095

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress

**Publish your work in this journal**

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S405817>